2010
Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy
Chao H, Mayer T, Concato J, Rose M, Uchio E, Kelly K. Prostate Cancer, Comorbidity, and Participation in Randomized Controlled Trials of Therapy. Journal Of Investigative Medicine 2010, 58: 566. DOI: 10.2310/jim.0b013e3181cf9002.Peer-Reviewed Original ResearchCastrate-resistant prostate cancerPhase 3 RCTsProstate cancerClinical settingPhase 3 clinical trialsVeterans Affairs Connecticut Healthcare SystemGeneral oncology practiceAbnormal laboratory valuesPopulation of patientsRandomized Controlled TrialsComplete medical recordsSerious medical conditionProportion of menBackground RandomizedChemotherapy regimensCRPC patientsControlled TrialsMedical recordsClinical trialsOncology practiceInclusion criteriaLaboratory valuesCardiac diseaseMedical conditionsClinical care
2002
What is “biochemical failure” in prostate cancer?
Lagu T, Wells C, Penson D, Concato J. What is “biochemical failure” in prostate cancer? Journal Of Clinical Epidemiology 2002, 55: 631. DOI: 10.1016/s0895-4356(02)00425-0.Peer-Reviewed Original ResearchProstate-specific antigenPSA failureMedian timeType of treatmentPSA slopeProstate cancerPost-treatment prostate-specific antigenVeterans Affairs Healthcare SystemAge-matched menProportion of menBiochemical failureSurgical failureTreatment failureSurrogate endpointsTherapeutic radiationAbility of providersVA sitesActual therapyPatientsClinical phenomenaCancerKappa statisticsHealthcare systemMenAmerican Society